Frequency of pre-treatment may not increase the immune-related adverse events of RCC patients treated with nivolumab

Nivolumab has shown good prognosis in renal cell carcinoma (RCC) patients previously treated with targeted therapy. We aimed to study irAE (immune-related adverse event) due to nivolumab and numbers of previous treatment lines in RCC patients. Between October 2016 and November 2019, 114 patients wer...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Medicine (Baltimore)
Egile Nagusiak: Mizutani, Kosuke, Ito, Toshiki, Takahara, Kiyoshi, Ando, Ryosuke, Ishihara, Takuma, Yasui, Takahiro, Shiroki, Ryoichi, Miyake, Hideaki, Koie, Takuya
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Lippincott Williams & Wilkins 2021
Gaiak:
7300
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC8021322/
https://ncbi.nlm.nih.gov/pubmed/33787647
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MD.0000000000025402
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak